(Q37965580)

26 August 2017

title

Clinical pharmacokinetics of fingolimod (English)

1 reference

26 August 2017

1 reference

Olivier J David

1

1 reference

26 August 2017

John M Kovarik

series ordinal

2

1 reference

26 August 2017

Robert L Schmouder

series ordinal

3

1 reference

26 August 2017

publication date

1 January 2012

1 reference

Clinical Pharmacokinetics

26 August 2017

published in

1 reference

26 August 2017

volume

51

1 reference

26 August 2017

issue

1

1 reference

26 August 2017

page(s)

15-28

1 reference

https://scigraph.springernature.com/pub.10.2165/11596550-000000000-00000

26 August 2017

exact match

0 references

cites work

The immune modulator FTY720 targets sphingosine 1-phosphate receptors

1 reference

https://api.crossref.org/works/10.2165%2F11596550-000000000-00000

Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596550-000000000-00000

FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596550-000000000-00000

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596550-000000000-00000

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596550-000000000-00000

Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596550-000000000-00000

FTY720 pharmacokinetics in mild to moderate hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596550-000000000-00000

Fingolimod (FTY720) in severe hepatic impairment: pharmacokinetics and relationship to markers of liver function

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596550-000000000-00000

Changes in plasma protein binding have little clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596550-000000000-00000

Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596550-000000000-00000

Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596550-000000000-00000

FTY720 and cyclosporine: evaluation for a pharmacokinetic interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596550-000000000-00000

Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose fingolimod (FTY720) in adolescents with stable renal transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596550-000000000-00000

Ketoconazole increases fingolimod blood levels in a drug interaction via CYP4F2 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596550-000000000-00000

The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596550-000000000-00000

Oral fingolimod (FTY720) for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596550-000000000-00000

A mechanistic study to assess whether isoproterenol can reverse the negative chronotropic effect of fingolimod

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596550-000000000-00000

The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596550-000000000-00000

CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis

21 January 2018

1 reference

12 December 2020

Ethnic sensitivity study of fingolimod in white and Asian subjects

1 reference

12 December 2020

First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients

1 reference

12 December 2020

FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology

1 reference

12 December 2020

Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects

1 reference

12 December 2020

Exposure-efficacy relationships of a fingolimod-everolimus regimen in kidney transplant patients at risk for delayed graft function

1 reference

12 December 2020

Absorption and disposition of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in healthy volunteers: a case of xenobiotic biotransformation following endogenous metabolic pathways

1 reference

12 December 2020

10.2165/11596550-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

26 August 2017

1023049216

0 references

1 reference